Analysts think CGON stock price could increase by 228%
Apr 15, 2025, 11:25 AM
20.67%
What does CGON do
CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
8 analysts think CGON stock price will increase by 228.13%. The current median analyst target is $65.79 compared to a current stock price of $20.05. The lowest analysts target is $55.55 and the highest analyst target is $86.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.